No Cover Image

Journal article 624 views 147 downloads

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data

Richard A Chudleigh, Julia Platts, Steve Bain Orcid Logo

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume: 13, Pages: 433 - 438

Swansea University Author: Steve Bain Orcid Logo

  • 53565.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution Non Commercial unported, v3.0 License (CC-BY-NC).

    Download (278.86KB)

Check full text

DOI (Published version): 10.2147/dmso.s193693

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (Q...

Full description

Published in: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
ISSN: 1178-7007
Published: Informa UK Limited 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa53565
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Glucagon-like peptide-1 (GLP-1) receptor agonists have been available as glucose-lowering therapies for people with type 2 diabetes since 2006, when twice-daily exenatide was licenced. Since then, advances in peptide chemistry and delivery have allowed for once-daily and more recently once-weekly (QW) delivery of peptides in this class and there are currently three QW “long-acting” GLP-1 receptor agonists available in clinical practice. This short review describes the therapeutic landscape that is occupied by the modern type 2 diabetes glucose-lowering therapies with a particular focus on long-acting GLP-1 receptor agonists. The efficacy and side-effect profiles of the available QW GLP-1 receptor agonists are discussed, focusing on head-to-head clinical trial comparisons. There is also an appraisal of the cardiovascular outcome trials, for which there has been an assessment of each of the QW GLP-1 receptor agonists, leading to clinical conclusions regarding their comparative effectiveness.
Keywords: GLP-1, type 2 diabetes, cardiovascular trial
College: Faculty of Medicine, Health and Life Sciences
Start Page: 433
End Page: 438

Similar Items